All meta-analyses about cell therapy showed that for patients with cardiomyopathy mainly DCM, this intervention could significantly improve 6-MWD, NYHA function classification, and LVEF, and reduce BNP/NT-pro BNP. The gene discussed is NPPB; the disease is familial dilated cardiomyopathy.